Premium
Expression of circulating miR‐17, miR‐25, and miR‐133 in breast cancer patients
Author(s) -
Hesari AmirReza,
Azizian Mitra,
Darabi Hassan,
Nesaei Abolfazl,
Hosseini Seyede Atefe,
Salarinia Reza,
Motaghi Amir Ali,
Ghasemi Faezeh
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27984
Subject(s) - microrna , breast cancer , downregulation and upregulation , metastasis , oncology , medicine , stage (stratigraphy) , real time polymerase chain reaction , cancer , cancer research , reverse transcriptase , reverse transcription polymerase chain reaction , polymerase chain reaction , gene expression , gene , biology , paleontology , biochemistry
One of the most lethal cancers among women is breast cancer. MicroRNAs (miRNAs) can be of great importance in the early detection of breast cancer. This study aimed to investigate some miRNAs in the serum of patients with breast cancer compared with the control group. Total RNA was extracted from the serum of patients with breast cancer and healthy volunteers. The expression levels of miRNAs and the genes were assessed using real‐time reverse transcriptase‐polymerase chain reaction with specific primers. Our data showed that miR‐25 and miR‐133 were downregulated, and miR‐17 was upregulated in patients with breast cancer. Upregulation of miR‐17 is related to the poor survival time and increased cell proliferation. The reduced expression of miR‐133 and miR‐25 is significantly associated with clinical stage, metastasis, and survival time of patients with breast cancer. Expressions of miRNAs miR‐17, miR‐25, and miR‐133 are altered in patients with clinical stage, metastasis, poor survival time.